Short-Term Correlations between Clinical and MR Imaging Findings in Relapsing-Remitting Multiple Sclerosis

References

1. ↵
   Rovaris M, and Filippi M. Magnetic resonance techniques to monitor disease evolution and treatment trial outcomes in multiple sclerosis. Curr Opin Neurol 1999;12:337–344

   CrossRefPubMedWeb of Science
2. ↵
   Filippi M, Horsfield MA, Ader HJ, et al. Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis. Ann Neurol 1998;43:499–506

   CrossRefPubMedWeb of Science
3. ↵
   Filippi M, Paty DW, Kappos L, et al. Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology 1995;45:255–260

   Abstract/FREE Full Text
4. Molyneux PD, Filippi M, Barkhof F, et al. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann Neurol 1998;43:332–339

   CrossRefPubMedWeb of Science
5. Weiner HL, Guttmann CRG, Khoury SJ, et al. Serial magnetic resonance imaging in multiple sclerosis: correlation with attacks, disability and disease stage. J Neuroimmunol 2000;104:164–173

   CrossRefPubMedWeb of Science
6. ↵
   Rovaris M, Comi G, Rocca MA, et al. Relevance of hypointense lesions on fast fluid-attenuated inversion recovery MR images as a marker of disease severity in cases of multiple sclerosis. AJNR Am J Neuroradiol 1999;20:813–820

   Abstract/FREE Full Text
7. ↵
   Grimaud J, Barker GJ, Wang L, et al. Correlation of magnetic resonance imaging parameters with clinical disability in multiple sclerosis: a preliminary study. J Neurol 1999;246:961–967

   CrossRefPubMedWeb of Science
8. ↵
   Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced MRI for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Lancet 1999;353:964–969

   CrossRefPubMedWeb of Science
9. ↵
   Koudriavtseva T, Thompson AJ, Fiorelli M, et al. Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1997;62:285–287

   Abstract/FREE Full Text
10. ↵
    Losseff N, Kingsley D, McDonald WI, et al. Clinical and magnetic resonance imaging predictors of disability in primary and secondary progressive multiple sclerosis. Multiple Sclerosis 1996;1:218–222

    PubMed
11. ↵
    Molyneux PD, Barker GJ, Barkhof F, et al. Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS. Neurology 2001;57:2191–2197

    Abstract/FREE Full Text
12. ↵
    Smith ME, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol 1993;33:480–489

    CrossRefPubMedWeb of Science
13. ↵
    Tubridy N, Coles AJ, Molyneux P, et al. Secondary progressive multiple sclerosis: the relationship between short-term MRI activity and clinical features. Brain 1998;121:225–231

    Abstract/FREE Full Text
14. ↵
    Filippi M, Horsfield MA, Morrissey SP, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994;44:635–641

    Abstract/FREE Full Text
15. ↵
    Brex PA, Ciccarelli O, O’Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002;346:158–164

    CrossRefPubMedWeb of Science
16. ↵
    Paty DW, Li DKB. The UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662–667

    Abstract/FREE Full Text
17. ↵
    Simon JH, Jacobs DL, Campion M, et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. Ann Neurol 1998;43:79–87

    CrossRefPubMedWeb of Science
18. Li DKB, Paty DW. The UBC MS/MRI Analysis Research Group and the PRISMS Study Group. Magnetic resonance imaging results of the PRISMS trial—a randomized, double-blind, placebo-controlled study of interferon-beta 1a in relapsing-remitting multiple sclerosis. Ann Neurol 1999;49:197–206
19. Paolillo A, Coles AJ, Molyneux PD, et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 1999;53:751–757

    Abstract/FREE Full Text
20. ↵
    Sorensen PS, Wanscher B, Jensen CV, et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998;50:1273–1281

    Abstract/FREE Full Text
21. ↵
    Sormani MP, Rovaris M, Bagnato F, et al. Sample size estimations for MRI-monitored trials of MS comparing new vs standard treatments. Neurology 2001;57:1883–1885

    Abstract/FREE Full Text
22. ↵
    Comi G, Filippi M, Wolinsky JS. The European/Canadian Glatiramer Acetate Study Group. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001;49:290–297

    CrossRefPubMedWeb of Science
23. ↵
    Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227–231

    CrossRefPubMedWeb of Science
24. ↵
    Lublin FD, Reingold SC. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907–911

    Abstract/FREE Full Text
25. ↵
    Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444–1452

    Abstract/FREE Full Text
26. ↵
    Miller DH, Barkhof F, Berry I, Kappos L, Scotti G, Thompson AJ. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry 1991;54:683–688

    Abstract/FREE Full Text
27. ↵
    Rovaris M, Bastianello S, Capra R, Comi G, Yousry TA, Filippi M. Correlation between enhancing lesion number and volume on standard and triple dose gadolinium-enhanced brain MRI scans from patients with multiple sclerosis. Magn Reson Imaging 1999;17:985–988

    CrossRefPubMedWeb of Science
28. ↵
    Rocca MA, Falini A, Colombo B, Scotti G, Comi G, Filippi M. Adaptive functional changes in the cerebral cortex of patients with nondisabling MS correlate with the extent of brain structural damage. Ann Neurol 2002;51:330–339

    CrossRefPubMedWeb of Science
29. ↵
    Rovaris M, Barkhof F, Bastianello S, et al. Multiple sclerosis: interobserver agreement in reporting active lesions on serial brain MRI using conventional spin echo, fast spin echo, fast fluid-attenuated inversion recovery and post-contrast T1-weighted images. J Neurol 925.1999;246:920–925

    CrossRefPubMedWeb of Science
30. ↵
    Mainero C, De Stefano N, Iannucci G, et al. Correlates of MS disability assessed in vivo using aggregates of MR quantities. Neurology 2001;56:1331–1334

    Abstract/FREE Full Text
31. ↵
    Wolinsky JS, Narayana PA, Johnson KP. The Copolymer 1 Multiple Sclerosis Study Group and the MRI Analysis Center. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis—MRI and clinical correlates. Multiple Sclerosis 2001;7:33–41

    Abstract/FREE Full Text
32. ↵
    van Walderveen MAA, Kamphorst W, Scheltens P, et al. Histopathologic correlate of hypointense lesions on T₁-weighted spin-echo MRI in multiple sclerosis. Neurology 1998;50:1282–1288

    Abstract/FREE Full Text
33. ↵
    McDonald WI, Miller DH, Barnes D. The pathological evolution of multiple sclerosis. Neuropathol Appl Neurobiol 1992;18:319–334

    CrossRefPubMedWeb of Science
34. ↵
    Ge Y, Grossman RI, Udupa JK, et al. Glatimerar acetate (Copaxone) treatment in relapsing-remitting MS. Quantitative MR assessment. Neurology 2000;54:813–817

    Abstract/FREE Full Text